Organization | Jiangsu Nhwa Pharmaceutical Co., Ltd.

Jiangsu Nhwa Pharmaceutical Co., Ltd. Report issue

For profit Phase 1 Phase 3 Phase 4

Founded: Xuzhou China (1978)

Status: No NME R&D (1978)

Organization Overview

First Clinical Trial

2009

NCT00866593

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2021

Timeline

NOW

Now

Alternative names

Jiangsu Nhwa Pharmaceutical Co., Ltd.

Active Ingredients

Drugs in Phase 4 Trials (7)

etomidate (amidate) (2 trials)

fentanyl (Innovar) (2 trials)

ketamine (ketalar) (1 trial)

midazolam (versed) (1 trial)

mivacurium (mivacron) (2 trials)

propofol (diprivan) (3 trials)

remifentanil (ultiva) (1 trial)

Drugs in Phase 3 Trials (1)

escitalopram (lexapro) (1 trial)

Drugs in Phase 1 Trials (3)

cy150112 (1 trial)

duloxetine (Cymbalta) (1 trial)

nh102 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Depression (Phase 3)

Depressive Disorder (Phase 3)

Fibrosis (Phase 2)

Liver Cirrhosis (Phase 2)

Liver Diseases (Phase 2)

Overview

Highest Phase: Phase 4
# of Trials: 8
# of Trial APIs: 11